CD274 and neoplasm: In contrast, in the other analyzed population, i.e., patients whose tumors expressed PD-L1 with a tumor proportion score equal to or greater than 50%, pembrolizumab achieved similar outcomes compared with the placebo, with a median disease-free survival not reached in either the pembrolizumab group (95% CI 44.3 to not reached) or the placebo group (95% CI 35.8 to not reached; HR 0.82 [95% CI 0.57–1.18]; p = 0.14).